Competitive Marketing Intelligence | Crayon

goBalto, Inc.

goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • First Mover Does Not Always a Market Leader Make
    No matter your industry, you likely feel intense pressure to get your product or service to market before your competitors. But if that's the first lesson in the Business 101 curriculum, the second should be that achieving "first-mover" status never guarantees success.
goBalto, Inc.
goBalto, Inc.
Blog Article
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • Will Special Interests Derail the Future of Personalized Medicine?
    Treatment of cancer using chemotherapy (chemo) drugs began soon after WWII, when a compound called nitrogen mustard was studied and found to work against cancer in the lymph nodes. In the years that followed, many chemo drugs have been developed that work by non-selectively inhibiting rapidly dividing cells.
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • 10 Tips for Selecting High Performing Clinical Sites
    Investigative sites are the heart and soul of clinical trials, essential to ensuring the efficacy and safety of pharmaceutical compounds in humans. Site selection is pivotal to the successful execution of clinical trials, which are not only long and bureaucratic, but are also experiencing diminishing returns.
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • Why is there such Inefficiency in Site Selection?
    This question is often asked about an industry deeply rooted in paper-based, spreadsheet tools for clinical trial conduct. Study teams have continued to rely on these older tools and relationships with principal investigators that have developed over time to select sites, building an institutional knowledge about specific sites based on previous studies.
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • Accelerating Innovation to Cut Drug Prices
    Americans spend a staggering amount of money for prescription drugs, and the prices keep rising. Cases of corporate greed like the infamous Martin Shkreli, former CEO of Turing Pharmaceuticals who increased the price of the life-saving medication Daraprim by 5,000 percent, have become the public face of the entire industry.
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

goBalto, Inc.
goBalto, Inc.
Blog Article
goBalto, Inc.
goBalto, Inc.
Blog Article
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • A Step Change in Study Startup Efficiency
    "Activate features such as: alerts and to-do lists, role based process flows, milestone tracking (including those on the critical path), and IP release checklists helped drive productivity by creating a central repository with the right supporting workflows."
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • Barriers to Increased Participation of Minorities in Clinical Trials
    Clinical trials are at the heart of the process for bringing new medicines to patients. One of the most critical aspects to the conduct of any clinical trial is identifying the right group of people to include in the study. Unfortunately, many of the clinical trials conducted in the United States suffer from a lack of diversity, with minority populations being consistently underreprese...
  • Moving Beyond Clinical and Operational Metrics in Study Startup
    Metrics are central to efforts to rein in clinical trials that are either poorly initiated or have incurred unforeseen events, which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials.
  • Webinar: Eliminating the Three Evil E's in Study Startup
    Save your seat for this upcoming webinar! A paradigm shift is needed in order to eliminate the three evil "e's" – email, Excel, and e-meetings – long associated with starting clinical trials.
  • Growing Complexity and Risks in Clinical Trials
    Clinical trials for pharmaceutical products continue to grow in complexity and scope. Research conducted by the Tufts Center for the Study of Drug Development (CSDD) during the past 15 years has demonstrated that, compared to 10 years ago, protocols have more endpoints, procedures, eligibility criteria, CRF (case report form) pages, amendments, and investigative sites—complicated furth...
  • Fighting the Commoditization of Sites: It Starts with the Site Initiation Visit (SIV)
    Despite advancements in clinical research technology over the last decade, recent research from the Tufts Center for the Study of Drug Development (CSDD) suggests that we are not conducting site activation any faster today than we did 20 years ago.
  • Clinical Trial to Patient Matching
    Despite advancements in clinical research technology over the last decade, recent research from the Tufts Center for the Study of Drug Development (CSDD) suggests that we are not conducting site activation any faster today than we did 20 years ago.
  • To you it’s a document. To me it’s my life.
    T.J. Sharpe is an ordinary man with an extraordinary story. Faced with the prospect of a Stage IV Melanoma diagnosis back in 2012, he vowed to never give up, determined to see his two young children grow up with a father.
  • Could Gamification Improve Clinical Trials?
    The gamification of many aspects of our culture is well under way, and some researchers are even beginning to consider the integration of gamification principles into clinical trials.
  • Webinar: Why are Metrics Important to Starting Clinical Trials?
    Save your seat for this upcoming webinar! This question may seem counter intuitive, as we are exposed almost daily to the dire performance of clinical trials and their spiraling costs resulting from incurred delays.
  • A Build vs. Buy Look at Study Activation
    With the advent of technology for clinical trials, an old argument plays out each time a new one is introduced. Should stakeholders build their own solution internally or buy an off-the-shelf tool designed for a specific purpose?
  • Me-Too's: The Carbon Copy "Innovators"
    There has been a long-running debate in the pharmaceutical industry about the value of being first to market. Companies spend considerable resources seeking to increase the odds of beating their competitors to market and often fret about the commercial disadvantage of being late.
  • Why are Metrics Important to Starting Clinical Trials?
    This question may seem counter intuitive, as we are exposed almost daily to the dire performance of clinical trials and their spiraling costs resulting from incurred delays.
  • Webinar: Are Delays in Clinical Trials due to a lack of Experienced CRAs?
    Save your seat for this upcoming webinar! The clinical research industry is experiencing a concerning global shortage of experienced Clinical Research Associates (CRAs), with many sponsors and CROs finding themselves in a never-ending recruitment cycle.
  • Dangers lurk in an eClinical Monopoly
    Clinical Research Organizations (CROs) are often portrayed as the bastions of innovation in the pharmaceutical industry when it comes to running clinical trials, which is not surprising given that outsourcing of trials is estimated to exceed 70% by 2020, and process optimization is key to both their differentiation strategy and increased margins.
  • Eliminating the three evil “e’s” from Starting Clinical Trials
    Clinical trials are the bridge to medical innovation. Most people don't think about the origins of the drug they receive or the medical procedures they undergo on a regular basis. Yet every drug, diagnostic test, surgical procedure – medical treatment in any shape or form – finds its origins in a single source: research.
  • 10 Tips for Enabling Better CRO-Sponsor Collaborations
    The outsourcing of clinical research activities is anticipated to increase steadily to 72% by 2020, up from just 23% in 2012. When we think of outsourcing, we need to remind ourselves of the Sponsor and CRO goals.
  • Webinar: Get Selected - How to Attract Sponsors and CROs
    Save your seat for this upcoming webinar! Attracting sponsors/CROs in today's competitive clinical trials landscape and maintaining those relationships is critical for sites that want to get selected for future studies.
  • goBalto Study Startup Summit Attracts Leading Pharmaceutical and CRO Organizations
    Engagement reflects adoption of industry proven study startup solutions.
  • Securing the High Ground
    An interesting take away from the recent Tufts CSDD report is the renewed interest in study startup (SSU) as an area of focus, that many organizations engaged in clinical trials are activity pursuing whether through innovation projects, expanded budgets or dedicated SSU teams.
  • Automate SOPs to Streamline Study Startup
    Standard Operating Procedures (SOP) rarely grab the spotlight like transformational technologies or newer strategies, such as risk-based monitoring or Quality by Design. But, SOPs deserve some love. With their coveted goal of improving operational efficiency, they have long been fundamental to many industries, and the clinical trials sector is no exception.
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

  • Co-Opting Innovation: How Startups and Big Companies Together Accelerate Innovation
    The race to innovate is increasingly a top priority for businesses across all sectors. The obvious fact is that only a tiny percentage of companies will prevail. What seems less obvious is that innovation almost always comes from small companies.
  • The Importance of Ethnic Diversity in Clinical Trials
    Clinical trials are at the heart of the process for bringing new medicines to patients. One of the most critical aspects to the conduct of any clinical trial is identifying the right group of people to include in the study. Unfortunately, many of the clinical trials conducted in the United States suffer from a lack of diversity, with minority populations being consistently underreprese...
goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

goBalto, Inc.
goBalto, Inc.
Blog Article

New blog articles detected.

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in